The Dublin-based bio-pharmaceutical company reported earnings of 63 cents per share, higher than Wall Street's forecasts for 62 cents per share. Revenue of $244.5 million beat analysts' forecasts for revenue of $240.82 million.
Additionally, Horizon Pharma projected 2016 revenue to range between $1.03 billion and $1.05 billion, in-line with Wall Street's estimates for $1.03 billion.
"We exceeded all of our original financial goals while at the same time significantly expanding our patient access program, HorizonCares, to thousands of patients at a value of more than $1 billion in 2015," CEO Timothy Walbert said in a statement.
Horizon Pharma stock is currently down 14.96% to $16.83 in mid-morning trading on Monday. It is unclear why.
Separately, recently, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author.
TheStreet Ratings rates this stock as a "sell" with a ratings score of D+. This is driven by several weaknesses, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The area that we feel has been the company's primary weakness has been its feeble growth in its earnings per share.
You can view the full analysis from the report here: HZNP